^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:certepetide (LSTA1) (Capillary permeability modulator, NRP1 modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cend Therapeutics Press Release
    Title:

    Cend Therapeutics’ CEND-1 Granted Fast Track Designation for Pancreatic Cancer

    Published date:
    06/29/2021
    Excerpt:
    SAN DIEGO...The US Food and Drug Administration (FDA) has granted Fast Track Development (FTD) status for Cend’s investigational drug, CEND-1, for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with gemcitabine/nab-paclitaxel.
    Secondary therapy:
    gemcitabine + albumin-bound paclitaxel